T2 Biosystms Stock Price To Earnings To Growth
| TTOO Stock | USD 0.50 0.01 2.04% |
T2 Biosystms fundamentals help investors to digest information that contributes to T2 Biosystms' financial success or failures. It also enables traders to predict the movement of TTOO Stock. The fundamental analysis module provides a way to measure T2 Biosystms' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to T2 Biosystms stock.
TTOO | Price To Earnings To Growth |
T2 Biosystms Company Price To Earnings To Growth Analysis
T2 Biosystms' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
TTOO Price To Earnings To Growth Driver Correlations
Understanding the fundamental principles of building solid financial models for T2 Biosystms is extremely important. It helps to project a fair market value of TTOO Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since T2 Biosystms' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of T2 Biosystms' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of T2 Biosystms' interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
TTOO Price Earnings To Growth Ratio
Price Earnings To Growth Ratio |
|
Based on the latest financial disclosure, T2 Biosystms has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
TTOO Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses T2 Biosystms' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of T2 Biosystms could also be used in its relative valuation, which is a method of valuing T2 Biosystms by comparing valuation metrics of similar companies.T2 Biosystms is currently under evaluation in price to earnings to growth category among its peers.
TTOO Fundamentals
| Return On Equity | -6.22 | ||||
| Return On Asset | -0.9 | ||||
| Operating Margin | (4.91) % | ||||
| Current Valuation | 27.34 M | ||||
| Shares Outstanding | 21.04 M | ||||
| Shares Owned By Insiders | 10.17 % | ||||
| Shares Owned By Institutions | 73.51 % | ||||
| Number Of Shares Shorted | 1.02 M | ||||
| Price To Earning | (2.04) X | ||||
| Price To Book | 14.50 X | ||||
| Price To Sales | 1.46 X | ||||
| Revenue | 7.19 M | ||||
| Gross Profit | (24.77 M) | ||||
| EBITDA | (43.88 M) | ||||
| Net Income | (50.08 M) | ||||
| Cash And Equivalents | 13.21 M | ||||
| Cash Per Share | 1.87 X | ||||
| Total Debt | 49.5 M | ||||
| Debt To Equity | 6.64 % | ||||
| Current Ratio | 1.87 X | ||||
| Book Value Per Share | (6.91) X | ||||
| Cash Flow From Operations | (48.14 M) | ||||
| Short Ratio | 1.26 X | ||||
| Earnings Per Share | (0.03) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 113 | ||||
| Beta | 0.38 | ||||
| Market Capitalization | 10.48 M | ||||
| Total Asset | 34.8 M | ||||
| Retained Earnings | (584.3 M) | ||||
| Working Capital | (30.96 M) | ||||
| Current Asset | 77.78 M | ||||
| Current Liabilities | 18.54 M | ||||
| Net Asset | 34.8 M |
About T2 Biosystms Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze T2 Biosystms's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of T2 Biosystms using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of T2 Biosystms based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether T2 Biosystms offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of T2 Biosystms' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of T2 Biosystms Stock. Outlined below are crucial reports that will aid in making a well-informed decision on T2 Biosystms Stock: Check out T2 Biosystms Piotroski F Score and T2 Biosystms Altman Z Score analysis. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of T2 Biosystms. If investors know TTOO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about T2 Biosystms listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.03) | Revenue Per Share 0.999 | Quarterly Revenue Growth (0.01) | Return On Assets (0.90) | Return On Equity (6.22) |
The market value of T2 Biosystms is measured differently than its book value, which is the value of TTOO that is recorded on the company's balance sheet. Investors also form their own opinion of T2 Biosystms' value that differs from its market value or its book value, called intrinsic value, which is T2 Biosystms' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because T2 Biosystms' market value can be influenced by many factors that don't directly affect T2 Biosystms' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between T2 Biosystms' value and its price as these two are different measures arrived at by different means. Investors typically determine if T2 Biosystms is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, T2 Biosystms' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.